A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)

Completed

• Conditions: Ankylosing Spondylitis (AS)

• Registration Number: NCT03505892
• Lead Sponsor: AbbVie

Brief Summary

The objectives of this prospective observational study is to explore 1-year clinical response via both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) after initiation of adalimumab therapy in AS patients from routine clinical practices in Taiwan.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-03-30
• Study First Submitted QC: 2018-04-13
• Study First Posted: 2018-04-23
• Study Start: 2018-06-05
• Primary Completion: 2021-10-25
• Study Completion: 2021-10-25
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-19
• Last Update Posted: 2023-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

• Participants with confirmed AS.
• Participant will start adalimumab as treatment
• Participant must provide the written authorization form and agree to provide personal and/or health data prior to the entry into the study.

Read More

Exclusion Criteria

• Participant has been treated with any investigational drug or biologic within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Baseline Visit.
• Participants who fulfill any of the contraindications as per Humira label in Taiwan.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of participants that achieve 50% improvement of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24	24 Weeks after initiation of Humira therapy	This accounts for participants achieving 50% improvement in BASDAI.

Secondary Outcome Measures

Name	Time	Method
Percentages of participants whose disease activity states are moderate per ASDAS score	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
Changes of the frequency of overall extra-articular manifestations (EAM) of interest	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The change of the frequency of overall extra-articular manifestations (EAM) will be assessed.
Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The change in MASES score will be assessed.
Percentages of participants who achieve major improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 24	24 Weeks after initiation of Humira therapy	The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
Percentages of participants who achieve clinically important improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 24	24 Weeks after initiation of Humira therapy	The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
Percentages of participants who achieve clinically important improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS)	Every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
Percentages of participants who achieve major improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS)	Every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
Changes of the respective frequency of each EAM	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The changes of the respective frequency of each EAM will be assessed.
Changes in the percentage of participants who have enthesitis of the plantar fascia or Achilles tendon	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The change in the percentage of participants who have enthesitis of the plantar fascia or Achilles tendon will be assessed.
Percentage of participants that achieve 50% improvement of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)	Every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	This accounts for participants achieving 50% improvement in BASDAI.
Percentages of participants whose disease activity states are inactive per ASDAS score	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.
Change in Tender Joint Counts (TJC)	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The change of TJC (0-46), in participants who had peripheral arthritis (≥1 swollen joint) at baseline will be assessed.
Change in Swollen Joint Counts (SJC)	At Week 0 (Baseline) and every 12 weeks' follow-up after initiation of Humira therapy (approximately up to 58 weeks)	The change of SJC (0-44), in participants who had peripheral arthritis (≥1 swollen joint) at baseline will be assessed.

Trial Locations

Locations (1)

Hualien Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation; 🇨🇳 Hualien City, Taiwan